title: Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs.
abstract: We demonstrated that hydrophobic derivatives of the nonsteroidal anti-inflammatory drug (NSAID)flufenamic acid (FA), can be formed into stable nanometer-sized prodrugs (nanoprodrugs) that inhibit the growth of glioma cells, suggesting their potential application as anticancer agent. We synthesized highly hydrophobic monomeric and dimeric prodrugs of FA via esterification and prepared nanoprodrugs using spontaneous emulsification mechanism. The nanoprodrugs were in the size range of 120 to 140 nm and physicochemically stable upon long-term storage as aqueous suspension, which is attributed to the strong hydrophobic interaction between prodrug molecules. Importantly, despite the highly hydrophobic nature and water insolubility, nanoprodrugs could be readily activated into the parent drug by porcine liver esterase, presenting a potential new strategy for novel NSAID prodrug design. The nanoprodrug inhibited the growth of U87-MG glioma cells with IC(50) of 20 μM, whereas FA showed IC(50) of 100 μM, suggesting that more efficient drug delivery was achieved with nanoprodrugs.
authors: Department of Neurosurgery, Cedars-Sinai Medical Center, 8631 West Third Street, Suite 800 East, Los Angeles, CA 90048, USA.
authors: Bong-Seop
authors: BS
authors: Lee
authors: Chi Woo
authors: CW
authors: Yoon
authors: Arsen
authors: A
authors: Osipov
authors: Nuriel
authors: N
authors: Moghavem
authors: Daniel
authors: D
authors: Nwachokor
authors: Rina
authors: R
authors: Amatya
authors: Rebekah
authors: R
authors: Na
authors: Joe L
authors: JL
authors: Pantoja
authors: Michael D
authors: MD
authors: Pham
authors: Keith L
authors: KL
authors: Black
authors: John S
authors: JS
authors: Yu
references: Nat Rev Cancer. 2001 Oct;1(1):11-21
references: 11900248
references: J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7
references: 11469677
references: Ann Clin Lab Sci. 2000 Jan;30(1):3-21
references: 10678579
references: Pharm Res. 2010 May;27(5):796-810
references: 20204471
references: Eur J Pharmacol. 2007 Sep 10;570(1-3):235-43
references: 17610876
references: Free Radic Biol Med. 2003 Oct 1;35(7):805-13
references: 14583345
references: FEBS Lett. 2000 Nov 3;484(2):139-43
references: 11068048
references: Pharm Res. 1993 Aug;10(8):1191-9
references: 8415407
references: Oncol Rep. 2005 Apr;13(4):559-83
references: 15756426
references: Redox Rep. 2003;8(4):179-86
references: 14599340
references: Semin Oncol. 2004 Apr;31(2 Suppl 7):36-44
references: 15179622
references: Mol Pharm. 2005 Sep-Oct;2(5):373-83
references: 16196490
references: Int J Pharm. 2004 Jan 9;269(1):89-100
references: 14698580
references: Int J Pharm. 2004 Aug 6;280(1-2):241-51
references: 15265563
references: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S140-9
references: 14508092
references: Biomaterials. 2008 Jun;29(18):2705-9
references: 18395249
references: J Urol. 2004 Feb;171(2 Pt 2):S59-62; discussion S62-3
references: 14713756
references: Clin Cancer Res. 1997 Oct;3(10):1679-83
references: 9815550
references: Br J Pharmacol. 1999 Nov;128(6):1121-32
references: 10578123
references: Fundam Clin Pharmacol. 2003 Jun;17(3):301-13
references: 12803569
references: Oncogene. 1995 Dec 21;11(12):2477-86
references: 8545104
references: Bioorg Med Chem. 2007 Jul 15;15(14):4767-74
references: 17509888
references: Nat Struct Biol. 2000 Apr;7(4):312-21
references: 10742177
references: Bioorg Med Chem Lett. 2006 Apr 1;16(7):1874-9
references: 16439128
references: Int J Pharm. 1999 Apr 15;180(2):151-60
references: 10370185
references: Mol Cancer. 2008 May 16;7:38
references: 18485224
references: Eur J Med Chem. 2001 Feb;36(2):109-26
references: 11311743
references: Am J Clin Oncol. 2003 Aug;26(4):S48-57
references: 12902856
references: Cancer J. 2004 May-Jun;10(3):145-52
references: 15285921
references: Science. 2001 Jan 26;291(5504):581-2
references: 11233414
references: Pharm Res. 1997 Nov;14(11):1634-9
references: 9434286
references: J Cell Biochem Suppl. 2000;34:97-102
references: 10762021
references: Clin Prostate Cancer. 2003 Sep;2(2):119-26
references: 15040874
references: Int J Pharm. 2009 May 8;372(1-2):112-24
references: 19166922
references: Eur J Pharm Sci. 2001 Sep;14(2):123-34
references: 11500258
references: Gastroenterology. 1996 Aug;111(2):445-54
references: 8690211
references: Bioorg Med Chem. 2007 Jan 15;15(2):951-61
references: 17126019